| Monograph: Lixisenatide | Compound monograph |
| Monograph: Pramlintide | Compound monograph |
| Monograph: Teduglutide | Compound monograph |
| Monograph: Tesamorelin | Compound monograph |
| Monograph: Sermorelin | Compound monograph |
| Monograph: CJC-1295 | Compound monograph |
| Monograph: Ipamorelin | Compound monograph |
| Monograph: Hexarelin | Compound monograph |
| Monograph: GHRP-6 | Compound monograph |
| Monograph: AOD-9604 | Compound monograph |
| Monograph: BPC-157 | Compound monograph |
| Monograph: TB-500 | Compound monograph |
| Monograph: Thymosin beta-4 | Compound monograph |
| Monograph: GHK-Cu | Compound monograph |
| Monograph: KPV | Compound monograph |
| Monograph: Larazotide acetate | Compound monograph |
| Monograph: Semax | Compound monograph |
| Monograph: Selank | Compound monograph |
| Monograph: DSIP | Compound monograph |
| Monograph: Epithalon | Compound monograph |
| Monograph: Thymosin alpha-1 | Compound monograph |
| Monograph: LL-37 | Compound monograph |
| Monograph: MOTS-c | Compound monograph |
| Monograph: SS-31 (elamipretide) | Compound monograph |
| Monograph: NAD+ (nicotinamide adenine dinucleotide) | Compound monograph |
| Monograph: Glutathione | Compound monograph |
| Monograph: 5-amino-1MQ | Compound monograph |
| Monograph: PT-141 (bremelanotide) | Compound monograph |
| Monograph: Melanotan-II | Compound monograph |
| Monograph: Kisspeptin-10 | Compound monograph |
| Monograph: Gonadorelin | Compound monograph |
| Standard CEI-MS-01: Determination of chromatographic purity of synthetic peptides by… | Methodological standard |
| Standard CEI-MS-02: Confirmation of peptide identity by liquid chromatography–tandem mass… | Methodological standard |
| Standard CEI-MS-03: Determination of peptide content and its distinction from… | Methodological standard |
| Standard CEI-MS-08: Related-substances profiling and the detection of isobaric impurities | Methodological standard |
| Standard CEI-MS-10: Identification and quantification of counter-ions in synthetic… | Methodological standard |
| Standard CEI-MS-13: Development and validation of a stability-indicating method for… | Methodological standard |
| Standard CEI-MS-19: Purity determination for peptides not retained by conventional… | Methodological standard |
| Standard CEI-MS-20: Photostability assessment of light-sensitive peptides | Methodological standard |
| Synthesis: Lixisenatide in type 2 diabetes mellitus: effect on the anchor outcome | Evidence synthesis |
| Synthesis: Thymosin alpha-1 in immune modulation and adjunctive immunotherapy… | Evidence synthesis |
| Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier… | Evidence synthesis |
| Synthesis: Thymosin beta-4 in cutaneous wound healing and tissue repair: effect… | Evidence synthesis |
| Synthesis: CJC-1295 in growth hormone deficiency and growth-hormone secretagogue… | Evidence synthesis |
| Synthesis: GHK-Cu in cutaneous wound healing and tissue repair: effect on the… | Evidence synthesis |
| Synthesis: Gonadorelin in growth hormone deficiency and growth-hormone… | Evidence synthesis |
| Synthesis: Kisspeptin-10 in growth hormone deficiency and growth-hormone… | Evidence synthesis |
| Synthesis: Larazotide acetate in inflammatory bowel disease and mucosal barrier… | Evidence synthesis |
| Synthesis: PT-141 (bremelanotide) in hypoactive sexual desire and erectile… | Evidence synthesis |
| Synthesis: Semax in cognitive performance and neuroprotection: effect on the… | Evidence synthesis |
| Synthesis: SS-31 (elamipretide) in primary mitochondrial myopathy and… | Evidence synthesis |
| Synthesis: Tesamorelin in hiv-associated lipodystrophy and excess visceral… | Evidence synthesis |
| Synthesis: Lixisenatide in type 2 diabetes mellitus: tolerability and… | Evidence synthesis |
| Synthesis: Thymosin alpha-1 in immune modulation and adjunctive immunotherapy… | Evidence synthesis |
| Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier… | Evidence synthesis |
| Synthesis: Thymosin beta-4 in cutaneous wound healing and tissue repair… | Evidence synthesis |
| Synthesis: CJC-1295 in growth hormone deficiency and growth-hormone secretagogue… | Evidence synthesis |
| Synthesis: GHK-Cu in cutaneous wound healing and tissue repair: tolerability and… | Evidence synthesis |
| Synthesis: Gonadorelin in growth hormone deficiency and growth-hormone… | Evidence synthesis |
| Synthesis: Kisspeptin-10 in growth hormone deficiency and growth-hormone… | Evidence synthesis |
| Synthesis: Larazotide acetate in inflammatory bowel disease and mucosal barrier… | Evidence synthesis |
| Synthesis: PT-141 (bremelanotide) in hypoactive sexual desire and erectile… | Evidence synthesis |
| Synthesis: Semax in cognitive performance and neuroprotection: tolerability and… | Evidence synthesis |
| Synthesis: SS-31 (elamipretide) in primary mitochondrial myopathy and… | Evidence synthesis |
| Synthesis: Tesamorelin in hiv-associated lipodystrophy and excess visceral… | Evidence synthesis |
| Synthesis: Lixisenatide in type 2 diabetes mellitus: durability of effect | Evidence synthesis |
| Synthesis: Thymosin alpha-1 in immune modulation and adjunctive immunotherapy… | Evidence synthesis |
| Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier… | Evidence synthesis |
| Synthesis: Thymosin beta-4 in cutaneous wound healing and tissue repair… | Evidence synthesis |
| Synthesis: CJC-1295 in growth hormone deficiency and growth-hormone secretagogue… | Evidence synthesis |